MGF (Mechano Growth Factor) Technical Specification Sheet
Molecular Properties
| Parameter |
Value |
| Chemical Name |
Mechano Growth Factor / IGF-1Ec |
| Amino Acid Sequence |
Tyr-Gln-Pro-Pro-Ser-Thr-Asn-Lys-Asn-Thr-Lys-Ser-Gln-Arg-Arg-Lys-Gly-Ser-Thr-Phe-Glu-Glu-Arg-Lys-Cys |
| Molecular Formula |
C₁₂₁H₂₀₀N₄₂O₃₉ |
| Molecular Weight |
2948.15 g/mol |
| CAS Number |
Not assigned (research peptide) |
| Sequence Length |
25 amino acids (C-terminal splice variant of IGF-1) |
| Isoform Type |
IGF-1Ec splice variant (exon 5 included) |
Physical Properties
| Property |
Specification |
| Appearance |
White to off-white sterile-filtered lyophilized powder |
| Solubility |
Soluble in sterile water or bacteriostatic water at ≥0.5 mg/mL; optimal at pH 7.0-8.0 |
| pH (1% solution) |
6.5 - 7.5 |
| Hygroscopicity |
Low to moderate; desiccated storage recommended |
| Solution Stability |
Stable at 4°C for 5-7 days; degradation accelerates at room temperature |
Analytical Specifications
| Test |
Specification |
| HPLC Purity |
≥98.0% |
| Mass Spectrometry |
Confirmed [M+H]⁺ = 2948.15 ± 1.0 Da |
| Peptide Content |
≥90% (by UV absorbance at 280 nm) |
| Endotoxin Level |
<1.0 EU/mg |
| Acetate Content |
≤8% |
| TFA Content |
≤0.5% |
| Water Content |
≤10% (Karl Fischer) |
Storage Parameters
| Condition |
Specification |
| Lyophilized Storage |
-20°C, desiccated with desiccant packet |
| Lyophilized Shelf Life |
24 months when stored properly at -20°C |
| Reconstituted Storage |
2-8°C for up to 7 days; -20°C for up to 2 months |
| Reconstitution Protocol |
Add 1-2 mL bacteriostatic water to 2 mg vial; gently swirl (do not shake vigorously) |
| Freeze-Thaw Cycles |
Maximum 2-3 cycles; single-use aliquots strongly recommended |
| Light Sensitivity |
Minimal; standard laboratory storage acceptable |
Research Dosing Reference
| Application |
Typical Dose Range |
Frequency |
Route |
| In Vitro Myoblast Studies |
10-100 ng/mL (3.4-34 nM) |
Single treatment or daily media change |
Culture media |
| Small Animal Models (Rodent) |
50-200 μg/kg |
Daily or post-exercise |
SC or IM injection |
| Muscle Repair Studies |
100-500 μg/kg |
3-5x per week for 2-4 weeks |
IM at injury site |
| Satellite Cell Activation |
25-100 ng/mL in vitro; 100 μg/kg in vivo |
Single dose or 24h intervals |
Local or SC |
Note: Dosing information is for research reference only. MGF is intended strictly for laboratory research. Not approved for human or veterinary use.
Key Research Studies
| Year |
Study Focus |
Key Findings |
| 1996 |
Discovery and characterization of MGF |
First identification of mechanically-induced IGF-1Ec splice variant in muscle tissue; expression peaks 2-4 hours post-exercise with unique C-terminal E-domain sequence |
| 2003 |
Satellite cell activation mechanisms |
MGF demonstrated superior satellite cell activation compared to systemic IGF-1; 25-49 amino acid E-peptide domain responsible for unique proliferative effects independent of IGF-1R |
| 2007 |
Muscle repair in injury models |
Local MGF injection (200 μg/kg) post-injury increased muscle fiber cross-sectional area by 25% vs controls; accelerated satellite cell proliferation detected within 48 hours |
| 2014 |
Neuroprotective and angiogenic properties |
MGF treatment protected motor neurons from oxidative stress; upregulated VEGF expression and capillary density in ischemic muscle models with ED₅₀ ~50 μg/kg |
Mechanism of Action
| Biological Pathway |
Description |
| Splice Variant Origin |
Alternative splicing of IGF-1 gene produces IGF-1Ec isoform; mechanical loading triggers exon 5 inclusion in muscle tissue |
| Satellite Cell Activation |
E-peptide domain activates quiescent satellite cells independent of IGF-1R; stimulates cell cycle entry and myoblast proliferation |
| Receptor Interactions |
Dual signaling: mature IGF-1 domain binds IGF-1R (PI3K/Akt pathway); E-peptide acts via separate, partially characterized receptor |
| Temporal Expression |
Rapid upregulation (2-4h) post-mechanical stimulus; precedes systemic IGF-1Ea expression (24-48h) |
| Half-Life |
~5-7 minutes (IV); rapid proteolytic degradation; local paracrine action predominates |
Quality Control Parameters
| Test Method |
Acceptance Criteria |
| Appearance (visual) |
White to off-white cake or powder; no discoloration |
| Reconstitution Test |
Complete dissolution within 2 minutes; clear to slightly opalescent solution |
| RP-HPLC (purity) |
Main peak ≥98.0% by area; no single impurity >0.5% |
| ESI-MS (identity) |
Observed mass within ±0.05% of theoretical |
| LAL Endotoxin Test |
<1.0 EU/mg |
Disclaimer: This product is intended for research use only. Not for human or veterinary diagnostic or therapeutic use. Handle according to institutional biosafety protocols.